News   /   Politics   /   Editor's Choice

Trump appears to admit COVID is 'running wild' in US

People wait in line for a COVID-19 test at a medical clinic near the Staten Island neighborhood of Tottenville on November 20, 2020 in New York City. (AFP photo)

President Donald Trump appears to have admitted that coronavirus is “running wild” across the US despite his statements throughout the election campaign that the United States was “rounding the turn” on the pandemic.

On Saturday night, the president took to Twitter, criticizing the “Fake News” for not saying that the disease is not just running wild in the US, but all over the world.

The Fake News is not talking about the fact that “Covid” is running wild all over the World, not just in the U.S. I was at the Virtual G-20 meeting early this morning and the biggest subject was Covid. We will be healing fast, especially with our vaccines!

— Donald J. Trump (@realDonaldTrump) November 21, 2020

His remarks come as new coronavirus infections in the US approached 200,000 a day, with cases surpassing 12 million in the country.

During the election campaign, Trump repeatedly asserted that the country would hear less about the pandemic after November 4.

His administration has been under harsh criticism for mishandling the crisis and he himself has played down the virus so far.

Meanwhile, US drug regulators on Saturday gave emergency approval to a COVID-19 antibody therapy which was used to treat Trump when he was sickened with the virus.

REGEN-COV2, a combination of two lab-made antibodies developed by drugmaker Regeneron, was shown to reduce COVID-19-related hospitalizations or emergency room visits in patients with underlying conditions.

"Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said Stephen Hahn, commissioner of the US Food and Drug Administration.

It is the second synthetic antibody treatment to obtain an emergency use approval (EUA) from the FDA after a similar one developed by Eli Lilly was granted the status on November 9.

According to the company, 80,000 patients might be able to receive the treatment by the end of November and approximately 300,000 patients in total are expected to have access to the treatment by the end of January 2021.

American patients can receive the treatment at no out-of-pocket cost under the terms of a US government program.

In spite of the ongoing spike in the cases, many Americans were heading to airports to travel for next week's Thanksgiving holiday, prompting some US states to impose new restrictions.


Press TV’s website can also be accessed at the following alternate addresses:

www.presstv.co.uk

SHARE THIS ARTICLE
Press TV News Roku